CARDLYTICS INC (CDLX)

US14161W1053 - Common Stock

3.87  +0.01 (+0.26%)

After market: 3.8 -0.07 (-1.81%)

Fundamental Rating

1

CDLX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 91 industry peers in the Media industry. Both the profitability and financial health of CDLX have multiple concerns. CDLX is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CDLX has reported negative net income.
In the past year CDLX has reported a negative cash flow from operations.
In the past 5 years CDLX always reported negative net income.
CDLX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -68.74%, CDLX is doing worse than 92.22% of the companies in the same industry.
CDLX's Return On Equity of -393.92% is on the low side compared to the rest of the industry. CDLX is outperformed by 86.67% of its industry peers.
Industry RankSector Rank
ROA -68.74%
ROE -393.92%
ROIC N/A
ROA(3y)-33.65%
ROA(5y)-24.34%
ROE(3y)-112.81%
ROE(5y)-77.12%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 53.54%, CDLX is doing good in the industry, outperforming 66.67% of the companies in the same industry.
CDLX's Gross Margin has improved in the last couple of years.
CDLX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.57%
GM growth 5Y2.94%

More info and screens

1

2. Health

2.1 Basic Checks

CDLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CDLX has more shares outstanding
The number of shares outstanding for CDLX has been increased compared to 5 years ago.
The debt/assets ratio for CDLX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -4.00, we must say that CDLX is in the distress zone and has some risk of bankruptcy.
CDLX has a worse Altman-Z score (-4.00) than 85.56% of its industry peers.
A Debt/Equity ratio of 3.06 is on the high side and indicates that CDLX has dependencies on debt financing.
With a Debt to Equity ratio value of 3.06, CDLX is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.06
Debt/FCF N/A
Altman-Z -4
ROIC/WACCN/A
WACC4.87%

2.3 Liquidity

CDLX has a Current Ratio of 1.18. This is a normal value and indicates that CDLX is financially healthy and should not expect problems in meeting its short term obligations.
CDLX has a Current ratio of 1.18. This is in the lower half of the industry: CDLX underperforms 62.22% of its industry peers.
A Quick Ratio of 1.18 indicates that CDLX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.18, CDLX is doing worse than 60.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 1.18

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.53% over the past year.
Looking at the last year, CDLX shows a decrease in Revenue. The Revenue has decreased by -3.00% in the last year.
Measured over the past years, CDLX shows a quite strong growth in Revenue. The Revenue has been growing by 15.46% on average per year.
EPS 1Y (TTM)67.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1600%
Revenue 1Y (TTM)-3%
Revenue growth 3Y18.27%
Revenue growth 5Y15.46%
Sales Q2Q%-15.12%

3.2 Future

Based on estimates for the next years, CDLX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.09% on average per year.
Based on estimates for the next years, CDLX will show a small growth in Revenue. The Revenue will grow by 1.11% on average per year.
EPS Next Y-76.25%
EPS Next 2Y-12.69%
EPS Next 3Y16.47%
EPS Next 5Y21.09%
Revenue Next Year-12.96%
Revenue Next 2Y-5.09%
Revenue Next 3Y-1.52%
Revenue Next 5Y1.11%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDLX. In the last year negative earnings were reported.
Also next year CDLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CDLX's earnings are expected to grow with 16.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.69%
EPS Next 3Y16.47%

More info and screens

0

5. Dividend

5.1 Amount

CDLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDLYTICS INC

NASDAQ:CDLX (12/24/2024, 8:01:47 PM)

After market: 3.8 -0.07 (-1.81%)

3.87

+0.01 (+0.26%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)01-27 2025-01-27/amc
Inst Owners69.44%
Inst Owner Change-9.83%
Ins Owners3.98%
Ins Owner Change12.56%
Market Cap196.67M
Analysts49.09
Price Target4.49 (16.02%)
Short Float %14.55%
Short Ratio9.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.26%
Min EPS beat(2)-16.71%
Max EPS beat(2)39.23%
EPS beat(4)3
Avg EPS beat(4)14.17%
Min EPS beat(4)-16.71%
Max EPS beat(4)39.23%
EPS beat(8)7
Avg EPS beat(8)47.92%
EPS beat(12)10
Avg EPS beat(12)38.21%
EPS beat(16)13
Avg EPS beat(16)25.79%
Revenue beat(2)1
Avg Revenue beat(2)2.17%
Min Revenue beat(2)-9.42%
Max Revenue beat(2)13.76%
Revenue beat(4)1
Avg Revenue beat(4)-1.4%
Min Revenue beat(4)-9.42%
Max Revenue beat(4)13.76%
Revenue beat(8)2
Avg Revenue beat(8)-0.77%
Revenue beat(12)4
Avg Revenue beat(12)0.47%
Revenue beat(16)7
Avg Revenue beat(16)0.62%
PT rev (1m)2.33%
PT rev (3m)-9.74%
EPS NQ rev (1m)-1.27%
EPS NQ rev (3m)-187.27%
EPS NY rev (1m)9.15%
EPS NY rev (3m)7.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-34.06%
Revenue NY rev (1m)1.35%
Revenue NY rev (3m)1.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.67
P/FCF N/A
P/OCF N/A
P/B 2.82
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS5.77
BVpS1.37
TBVpS-2.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.74%
ROE -393.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.54%
FCFM N/A
ROA(3y)-33.65%
ROA(5y)-24.34%
ROE(3y)-112.81%
ROE(5y)-77.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.57%
GM growth 5Y2.94%
F-Score4
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 3.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 70.18%
Cap/Sales 6.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.18
Quick Ratio 1.18
Altman-Z -4
F-Score4
WACC4.87%
ROIC/WACCN/A
Cap/Depr(3y)41.61%
Cap/Depr(5y)99.36%
Cap/Sales(3y)4.41%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1600%
EPS Next Y-76.25%
EPS Next 2Y-12.69%
EPS Next 3Y16.47%
EPS Next 5Y21.09%
Revenue 1Y (TTM)-3%
Revenue growth 3Y18.27%
Revenue growth 5Y15.46%
Sales Q2Q%-15.12%
Revenue Next Year-12.96%
Revenue Next 2Y-5.09%
Revenue Next 3Y-1.52%
Revenue Next 5Y1.11%
EBIT growth 1Y-77.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.37%
EBIT Next 3YN/A
EBIT Next 5Y36.02%
FCF growth 1Y50.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.55%
OCF growth 3YN/A
OCF growth 5YN/A